Nabla Bio, a Cambridge, MA-based company developing AI and wet-lab technologies, raised $26M in Series A funding.
The round was led by Radical Ventures with participation from all existing investors, and strategic collaborations with AstraZeneca, Bristol Myers Squibb Company and Takeda.
The company intends to use the funds to expand operations and development efforts.
Led by Surge Biswas and Frances Anastassacos, Nabla Bio develops integrated AI and wet-lab technologies that enable atomically precise drug design and high-throughput measurement of drug function, with an initial focus on antibodies targeting multipass membrane proteins, including for example, G protein-coupled receptors (GPCRs), ion channels, and transporters.
To maximize the patient impact of its platform, Nabla collaborates with pharmaceutical companies with a track record of drug development to expand their pipelines with high-quality drug candidates against some of the most challenging, high-impact targets. These collaborations also offer valuable insights into disease biology and platform development while offsetting a significant portion of R&D expense, enabling Nabla to grow quickly and sustainably.
FinSMEs
15/05/2024